Eukaryotic translation initiation factors as promising targets in cancer therapy

Table 1 Aberrant expression of eIFs in human cancer

eIFs	Dysregulation	Type of cancer
eIF1A/ eIF1AX	Mutation	Uveal melanomas, papillary thyroid carcinoma (PTC), anaplastic thyroid carcinomas (ATC), leptomeningeal melanocytic neoplasms (LMNs) [2, 108]
eIF2α	Overexpression	Non-Hodgkin’s lymphoma, melanocytic neoplasm, NSCLC, gastrointestinal cancer, and brain tumor [2, 109, 110]
eIF3a	Overexpression	Brain cancer, cervix cancer, lung cancer, stomach cancer and colorectal cancer [2, 10]
eIF3c	Overexpression	Meningioma and testicular seminoma [2]
eIF3e	Downregulation	Breast cancer, NSCLC and prostate cancer [2, 111]
eIF3f	Downregulation	Melanocytic neoplasm, pancreatic cancer, breast and ovary cancer [2, 112, 113]
eIF3h	Overexpression	Breast cancer, prostate cancer, hepatocellular carcinoma, NSCLC and colorectal cancer [2, 111, 114,115,116,117,118,119]
eIF4E	Overexpression/hyperphosphorylation	Breast cancer, lung cancer, prostate cancer, colorectal cancer, skin cancer, head and neck cancer and cervical cancer [2, 120,121,122,123,124,125]
eIF5A	Overexpression	Cervical cancer, NSCLC and colorectal cancer [2, 126]
eIF6	Overexpression	Colorectal cancer, head and neck carcinoma, malignant mesothelioma and NSCLC [2]

ISSN: 1478-811X